Lonza Expands Pharma & Biotech Footprint Increasing its Drug Product Services
Lonza announced today that its Pharma & Biotech segment is expanding its footprint for Parenteral Dosage Form development with a further build-out of its Drug Product Services (DPS). This investment will significantly expand both capability and capacity of DPS at the Stücki Science Park in Basel (CH) and will create more than 50 new positions. The expanded offering includes new capabilities for drug product process development.
DPS opened its laboratories in November 2016 with an initial focus on Formulation Development and Drug Product Analytical Development. This facility was recently granted a GMP license after a successful audit by Swissmedic allowing QC release and stability testing of drug products.
This significant expansion represents an important milestone in Lonza’s evolution to become a fully integrated drug development partner. With the recent acquisition of Capsugel, combined with DPS’s excellence in parenterals, we offer a wide range of services to meet our customers' drug product needs," said Marc Funk, COO of Lonza's Pharma & Biotech segment. "Our expansion in Basel also signals Lonza's strong commitment to the local community."
The DPS team provides a holistic approach to drug product development that anticipates and prevents problems early and helps ensure the product is optimal for manufacture, supply chain and patient use. The DPS team provides a complete portfolio of services for parenteral dosage forms including products for injection and infusion for intravenous, subcutaneous, and intraocular routes of administration.
These offerings also include specialized services, such as:
• Particulate identification, characterization and quantification
• Excipient and surfactant characterization
• Extractables and leachables assessment
• Container closure integrity testing
“The expansion of Drug Product Services reflects the value that Lonza brings to our pharma and biotech customers through exceptional experience, a strong scientific track record and state-of-the-art instrumental infrastructure which enables them to accelerate and de-risk Drug Product development and commercialization,” said Prof Dr. Hanns-Christian Mahler, Lonza’s Head of Drug Product Services.
This article has been republished from materials provided by Lonza. Note: material may have been edited for length and content. For further information, please contact the cited source.
Understanding Lung Cancer Cell Networks Helps Create Drug TreatmentsNews
A team of scientists has identified networks inside lung cancer cells that will help understand this cancer and fight it with drug treatments.READ MORE
Downward-Facing Mouse: Stretching Reduces Breast Cancer Tumor GrowthNews
Using a mouse model of breast cancer and a gentle stretching technique, researchers evaluated tumor growth as well as changes in molecular signals of immune response and inflammation resolution.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018